1Q 2015 and Recent Operational Highlights Direct De Novo petition for Ablatherm HIFU submitted to the FDA in April 2015 ; Treatment-driven revenue from the HIFU division increased 17% year-over-year; Revenue for first quarter 2015 totaled EUR 6.2 million ( USD 6.9 million ); Canadian regulatory
2014 and Recent Operational Highlights Record revenue in 2014 of EUR 26.8 million ( USD 35.4 million ); 11% growth over the previous year; Full-year HIFU revenue increased 70% over 2013; Strong Cash position of EUR 12.1 million ( USD 14.7 million ) as of December 31, 2014 ; Filing Direct De Novo
LYON, France , Feb. 26, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced a multi-national strategic OEM partnership with Quanta System, a leading manufacturer of medical lasers for surgical and other applications.
LYON, France , Jan. 9, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its Focal One HIFU device has been approved by Health Canada . With this approval, the Company is able to market the Focal One device for the treatment of
Highlights Revenues increased 27% year-over-year to EUR 20.3 million ( USD 27.4 million ) for the first nine months of 2014 HIFU revenue increased 114% year-over-year during first nine months of 2014 Positive operating income, excluding FDA -related costs, for three and nine months ended September
